Neuromyelitis Optica
·MeSH: Neuromyelitis Optica
Prevalence
30.0 / 100K
4 drugs in development·4 companies·1 clinical trial
Drug Pipeline by Phase
Approved(3)
Phase 4(1)
| Drug | Company |
|---|---|
| Eculizumab administration | Valneva SE (VALN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Neuromyelitis Optica?
BioSniper tracks 4 drugs in development for Neuromyelitis Optica across 4 companies.
How many clinical trials target Neuromyelitis Optica?
There are 1 clinical trial targeting Neuromyelitis Optica tracked by BioSniper.
What is the prevalence of Neuromyelitis Optica?
The estimated prevalence of Neuromyelitis Optica is approximately 30.0 per 100,000 population.
Deep-dive into Neuromyelitis Optica
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis